General Information of This Drug (ID: DMYURI6)

Drug Name
Raltegravir   DMYURI6
Synonyms
RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

54 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Acetazolamide + Raltegravir DCCU0B9 Acetazolamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Aprepitant + Raltegravir DC0GG2V Aprepitant Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Arfolitixorin + Raltegravir DCYXKHL Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Armodafinil + Raltegravir DC2DPIR Armodafinil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Auranofin + Raltegravir DCTEL6A Auranofin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Bepridil + Raltegravir DCVO4QR Bepridil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Carglumic acid + Raltegravir DCZTQOE Carglumic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Cerivastatin + Raltegravir DCAAS2P Cerivastatin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Chlorzoxazone + Raltegravir DC3DW5K Chlorzoxazone Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Clascoterone + Raltegravir DCFX7ZP Clascoterone Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Crotamiton + Raltegravir DCMSMVV Crotamiton Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Dactinomycin + Raltegravir DCLO3VT Dactinomycin Chronic myelogenous leukemia (Cell Line: KBM-7) [3]
Diazoxide + Raltegravir DCAYJRX Diazoxide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Dihydroergotamine + Raltegravir DCJO4I8 Dihydroergotamine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Docetaxel + Raltegravir DCV9D2P Docetaxel Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
ETHISTERONE + Raltegravir DC3YWDQ ETHISTERONE Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Flavonoid derivative 1 + Raltegravir DCXRV7G Flavonoid derivative 1 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
FORMESTANE + Raltegravir DCJ8GK4 FORMESTANE Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Gefitinib + Raltegravir DC757EH Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Idarubicin + Raltegravir DC6Q1TC Idarubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Imatinib + Raltegravir DCLKJAH Imatinib Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Lacosamide + Raltegravir DCZD34V Lacosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Linagliptin + Raltegravir DCJNOPM Linagliptin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Mebendazole + Raltegravir DCSL45X Mebendazole Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Meclofenamic acid + Raltegravir DCPBZZX Meclofenamic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Mefloquine + Raltegravir DC4KDHN Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Methotrexate + Raltegravir DCDU2T1 Methotrexate Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Mycophenolic acid + Raltegravir DCK98K5 Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Niclosamide + Raltegravir DC7FJDW Niclosamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Pazopanib HCl + Raltegravir DC24OPM Pazopanib HCl Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Pinacidil + Raltegravir DCU1G8A Pinacidil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
PMID28460551-Compound-2 + Raltegravir DCU9VUA PMID28460551-Compound-2 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Pyrazinamide + Raltegravir DCEYC9T Pyrazinamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Dantrolene DCVS3N7 Dantrolene Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Fomepizole DCHQS1U Fomepizole Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Triapine DCJ7844 Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + IT-141 DCG3RGD IT-141 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + LY03004 DCU43WK LY03004 Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Fenoprofen DC2Q5WD Fenoprofen Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Allopurinol DCBC3A7 Allopurinol Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Idarubicin DC1N5VV Idarubicin Glioblastoma? (Cell Line: T98G) [2]
Raltegravir + Abacavir DCUNDG5 Abacavir Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Methylene blue DCZU8SN Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Artemisinin DCQ4RDS Artemisinin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Leflunomide DCVZM4I Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Chlorambucil DCESKH1 Chlorambucil Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Doxorubicin DCK7680 Doxorubicin Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Acetohydroxamic Acid DCJO25J Acetohydroxamic Acid Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Azatadine DCKLQVU Azatadine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Tetracycline DCIKBTO Tetracycline Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Raltegravir + Cytarabine DCHT9OH Cytarabine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Trimethobenzamide + Raltegravir DC25S5H Trimethobenzamide Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Vinblastine + Raltegravir DCGBFKP Vinblastine Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
Zileuton + Raltegravir DCXBBV7 Zileuton Chronic myelogenous leukemia (Cell Line: KBM-7) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 54 DrugCom(s)
16 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Abacavir + Raltegravir DCVCU7P Abacavir HIV [4]
Amlodipine + Raltegravir DC5GQF8 Amlodipine HIV [5]
Atazanavir + Raltegravir DCK60JV Atazanavir HIV [6]
Boceprevir + Raltegravir DCUAY9A Boceprevir HIV Infections [7]
Citalopram + Raltegravir DC6PTSC Citalopram HIV [8]
Darunavir + Raltegravir DC6DLN4 Darunavir HIV-1 Infection [9]
Famotidine + Raltegravir DCGL2JR Famotidine HIV-1 Infection [10]
Lamotrigine + Raltegravir DC47DV7 Lamotrigine HIV Infection [11]
Lopinavir + Raltegravir DC3HPZB Lopinavir Human Immunodeficiency Virus Infection [12]
Omeprazole + Raltegravir DCYDJKZ Omeprazole HIV-1 Infection [10]
Tenofovir + Raltegravir DC85GHN Tenofovir HIV Infections [13]
Tenofovir + Raltegravir DCEHPPH Tenofovir HIV [14]
Emtricitabine + Raltegravir DCRSKBT Emtricitabine Primary Biliary Cholangitis [15]
Lamivudine + Raltegravir DCL834N Lamivudine HIV Infections [16]
Atorvastatin + Raltegravir DCNKSDC Atorvastatin Aging-related Inflammation in HIV-infected Patients [17]
Lamivudine + Raltegravir DCJC0HZ Lamivudine Hiv [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 ClinicalTrials.gov (NCT00765271) Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects
5 ClinicalTrials.gov (NCT01841593) A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers
6 ClinicalTrials.gov (NCT00768989) Phase IIB Pilot of Atazanavir + Raltegravir
7 ClinicalTrials.gov (NCT01288417) Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir
8 ClinicalTrials.gov (NCT01978782) Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).
9 ClinicalTrials.gov (NCT01641367) A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
10 ClinicalTrials.gov (NCT01000818) A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
11 ClinicalTrials.gov (NCT00618241) Pharmacokinetic Study on Raltegravir and Lamotrigine
12 ClinicalTrials.gov (NCT00711009) Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
13 ClinicalTrials.gov (NCT00977756) IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
14 ClinicalTrials.gov (NCT01214759) Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
15 ClinicalTrials.gov (NCT03954327) Combination Antiretroviral Therapy (cART) for PBC
16 ClinicalTrials.gov (NCT03311945) Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
17 ClinicalTrials.gov (NCT02577042) Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
18 ClinicalTrials.gov (NCT03205566) Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection